Calzada (CZD) AOD9604 Osteoarthritis and diseases related to...

  1. 20,536 Posts.
    lightbulb Created with Sketch. 1835
    Calzada (CZD) AOD9604 Osteoarthritis and diseases related to muscle mass loss The company has received positive results from in-vitro tests conducted on its peptide compound, AOD9604. These studies were conducted in separate cartilage and muscle cell experiments using animal cell lines and were designed to explore AOD9604’s commercial potential.

    http://www.pwc.com.au/industry/technology/assets/bioForum/BioForum-Ed39-Ch3-Apr12.pdf
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.